Northwest Biotherapeutics (NWBO) Total Non-Current Liabilities (2010 - 2026)

Northwest Biotherapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $35.1 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 19.99% year-over-year to $35.1 million in Q1 2026; TTM through Mar 2026 was $35.1 million, a 19.99% increase from a year earlier, with the FY2025 full-year figure at $37.2 million, down 0.73% from the prior year.
• Total Non-Current Liabilities slipped to $35.1 million in Q1 2026 per NWBO's latest filing, from $37.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $38.0 million in Q3 2025 and bottomed at $10.1 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $29.3 million (2025), against an average of $26.4 million.
• Across the five-year window, Total Non-Current Liabilities plunged 65.9% in 2022 and soared 186.81% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $10.4 million in 2022, then surged by 186.81% to $29.7 million in 2023, then rose by 25.97% to $37.4 million in 2024, then declined by 0.73% to $37.2 million in 2025, then slipped by 5.44% to $35.1 million in 2026.
• Per Business Quant, the three latest NWBO Total Non-Current Liabilities figures stand at $35.1 million (Q1 2026), $37.2 million (Q4 2025), and $38.0 million (Q3 2025).